Thousand Oaks mayor lauds ‘balanced growth,’ cites new mixed-use project
![](https://dev.pacbiztimes.com/wp-content/uploads/2017/03/1-T.O.-mixed-use-web-300x224.jpg)
Thousand Oaks mayor Al Adam gave the annual State of the City address on Dec. 8, centered around three things he said are most important to the city’s growth: jobs, the environment and housing. In his virtual address, Adam said the influx of biotech companies in recent years has been a big win for the Read More →
Read More →Amgen joins new cooperative trials for COVID treatment
![](https://dev.pacbiztimes.com/wp-content/uploads/2014/01/amgen-flagWEB-300x224.jpg)
With COVID-19 continuing to surge across the globe, a coalition of pharmaceutical companies including Thousand Oaks-based Amgen has announced a joint trial for new coronavirus treatments. Amgen, along with Takeda and UCB, are now collaborating to study methods of treatment for patients who are hospitalized due to COVID-19, the three companies announced. The trial enrolled Read More →
Read More →![Premium Content](https://dev.pacbiztimes.com/wp-content/themes/e9bqxucyjgdpwjvsw8/images/premium.gif)
Inphi, Marvell to form $40 billion chip giant
![](https://dev.pacbiztimes.com/wp-content/uploads/2016/02/inphi-squarelogo.png)
Marvell’s acquisition put’s Inphi’s Thousand Oaks operation in question
Read More →Amgen beats expectations in Q3 earnings report
![](https://dev.pacbiztimes.com/wp-content/uploads/2014/01/amgen-flagWEB-300x224.jpg)
Amgen, one of the biggest biopharmaceutical companies in the world, continued to see growth in the third quarter of 2020, despite the COVID-19 pandemic. The Thousand Oaks-based company saw total revenue of $6.4 billion for the quarter, up 12 percent from the third quarter of 2019. Earnings per share increased 5 percent to $3.43. Both Read More →
Read More →Teledyne reports earnings dip
![](https://dev.pacbiztimes.com/wp-content/uploads/2016/02/teledyne-technologies-logo-marker-bg.jpg)
Despite a dip in earnings and sales compared to last year, Teledyne Technologies beat analysts’ expectations with net income of $93.9 million in the third quarter, the company announced Oct. 21. Analysts estimated that Teledyne’s diluted earnings per share would be $2.36 in the third quarter, according to estimates compiled by the Wall Street Journal. Read More →
Read More →Arcutis shares up on news of public, private offerings
![](https://dev.pacbiztimes.com/wp-content/uploads/2019/10/Arcutis-logo-300x184.png)
Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →
Read More →